Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese~* No clinical evidence of gross genital lesion suggesting sexually-transmitted disease and no clinically present external genital warts~* Other inclusion criteria will be discussed with the investigator during screening~Exclusion Criteria:~* History of known prior vaccination with an HPV vaccine or plans to receive one outside the study~* History of external genital warts~* History of severe allergic reaction that required medical intervention~* Received immune globulin or blood-derived products in the past 6 months or plan to receive any before Month 7 of the study~* History of splenectomy, is currently immunocompromised, or has been diagnosed with immunodeficiency, Human Immunodeficiency Virus (HIV), lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition~* Received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical corticosteroids and certain regimens of systemic corticosteroids~* Known thrombocytopenia or coagulation disorder that would contraindicate intramuscular injections~* Ongoing alcohol or drug abuse within the past 12 months

- Gender: MALE
- Minimum Age: 16 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- V501 (Type: EXPERIMENTAL): Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.

Based on this trial design, predict the completion outcome and termination type (if applicable).